Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. To learn more about Dana-Farber and our momentum of discovery, please click here.
- Dana-Farber is the only hospital ranked in the top five nationally by U.S. News & World Report in both adult and pediatric cancer care.
- Dana-Farber is a national leader in conducting clinical trials, and currently has more than 1,100 active clinical trials.
- Dana-Farber has one of the largest hematology/oncology training programs in the country, which has produced more leaders in oncology than any other program in the nation.
- Dana-Farber is a founding member of Dana-Farber/Harvard Cancer Center, one of 57 NCI-designated Comprehensive Cancer Centers in the U.S.
- Dana-Farber’s faculty are among the most highly cited researchers in the world. More than 40 researchers were named to the “Highly Cited Researchers list” by the Institute for Scientific Information at Clarivate, demonstrating significant research influence among their peers.
- Recognizing excellence in nursing and patient care, Dana-Farber was awarded Magnet® status five consecutive times - an anchievement attained by fewer than 1% of hospitals nationwide.
- Dana-Farber was one of 1,000 U.S.-based organizations named to Newsweek’s annual list of “America’s Greatest Workplaces for Women 2025.”
- Benjamin L. Ebert, MD, PhD, was named President and CEO of Dana-Farber in October of 2024, and is the first Dana-Farber-trained oncologist to serve as president and CEO of the Institute.
- Dana-Farber faculty have been awarded two Nobel Prizes. William G. Kaelin Jr., MD, was the recipient of the Nobel Prize in Physiology or Medicine in 2019, along with two other physician-scientists, for their discoveries of how cells sense and adapt to oxygen availability. Baruj Benacerraf, MD, was awarded the Nobel Prize in Physiology in 1980 for his breakthrough genetic findings.
